A fluorescing nanoparticle that can find tumors, light up upon arrival and be activated with light to generate heat to destroy the cancer cells has been developed by a research team at Wake Forest Baptist Medical Center. This discovery overcomes the major problem in treating cancer: identifying the location of small tumors and treating them before they metastasize.
A study in which these nanoparticles - Hybrid Donor-Acceptor Polymer Particles, or H-DAPPs - successfully located and killed breast cancer skills in mice is published in the current issue of the journal ACS Applied Materials and Interfaces
‘New nanoparticle made by combining a heat-generating polymer with a light-emitting polymer allows detection and heat treatment of the tumor.’
"An unexpected result was how efficiently the nanoparticles localized to the tumors without any targeting agent," said the study's lead author, Nicole Levi-Polyachenko, Ph.D., associate professor of plastic and reconstructive surgery at Wake Forest School of Medicine, part of Wake Forest Baptist. "Achieving high enough levels of H-DAPPs within the tumor to allow it to be seen provides an advantage for knowing exactly where light should be applied to generate heat and kill the cancer cells."
Other investigators have developed nanoparticles to detect tumors or carry drugs, and Levi-Polyachenko's team has created polymers that strongly absorb infrared light and generate heat. Regarding the new nanoparticle, she said, "It was exciting to figure out the step for combining a heat-generating polymer with a light-emitting polymer to allow for detection and on-demand heat treatment."
H-DAPPs are made of electrically conductive polymers and are smaller than 100 nanometers (0.00000393701 of an inch) in diameter. Their small size and soft composition makes it easy for them to travel through the bloodstream to the tumor.
"There is much more research needed to ensure that H-DAPPs can safely be used in humans," Levi-Polyachenko said. "But we are enthusiastic about exploring the use of H-DAPPs with other cancer types and eventually in patients."